Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment

被引:0
作者
Giacomo Coltro
Mrinal M. Patnaik
机构
[1] Division of Hematology,Department of Medicine
[2] Mayo Clinic,undefined
来源
Current Oncology Reports | 2019年 / 21卷
关键词
Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Myeloproliferative neoplasms; Clonal architecture; Prognostication; Target therapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 513 条
[31]  
Finke CM(2010)Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value Blood. 116 3923-193
[32]  
Hanson CA(2018)Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents EBioMedicine 31 174-461
[33]  
Hodnefield JM(2013)Somatic SETBP1 mutations in myeloid malignancies Nat Genet 45 942-1417
[34]  
Knudson RA(2017)DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia Am J Hematol 92 56-3088
[35]  
Patnaik MM(2010)The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate Cancer Cell 17 225-377
[36]  
Itzykson R(2011)Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases Cancer Cell 19 17-5077
[37]  
Lasho T(2012)Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients Leukemia. 26 101-2256
[38]  
Kosmider O(2006)Characterization of Asxl1, a murine homolog of additional sex combs, and analysis of the Asx-like gene family Gene. 369 109-73
[39]  
Finke C(2011)Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms Leukemia. 25 1200-416
[40]  
Hanson C(2012)ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression Cancer Cell 22 180-2088